A review of low-dose-rate prostate brachytherapy - Techniques and outcomes

Journal of the National Medical Association

Volumn 102, Issue 6, 2010, Pages 500-510

  Marcus, David M ^a   Jani, Ashesh B ^a   Godette, Karen ^b   Rossi, Peter J ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Brachytherapy; Outcomes; Prostate cancer; Quality of life

Indexed keywords

CESIUM 131; IODINE 125; PALLADIUM 103;

BLADDER IRRITATION; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; ECHOGRAPHY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FECES INCONTINENCE; HEMATOCHEZIA; HUMAN; INTRAOPERATIVE PERIOD; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; RADIATION EXPOSURE; REVIEW; SEXUAL FUNCTION; URINARY FREQUENCY; URINARY TRACT OBSTRUCTION; URINARY URGENCY; URINE INCONTINENCE; MALE; METHODOLOGY; PROSTATE TUMOR; RADIATION RESPONSE; TREATMENT OUTCOME;

BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77954910355     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30559-9     Document Type: Review

References (53)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008.CA Cancer J Clin. 2008;58:71-96.
2. Aronowitz JN. Dawn of prostate brachytherapy: 1915-1930. Int J Radiat Oncol Biol Phys. 2002;54:712-718.
3. Hilaris BS. Brachytherapy in cancer of the prostate: an historical perspective. Semin Surg Oncol. 1997;13:399-405. (Pubitemid 27469223)
4. Zelefsky MJ, Eid JF. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998:40;129-133..
5. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250-1261.
6. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet. 2003;361:1045-1053. (Pubitemid 36351377)
7. Blasko JC, Mate T, Sylvester JE, et al. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol. 2002;12:81-94.
8. Nag S, Bice W, DeWyngaert K, et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 2000;46:221-230. (Pubitemid 30021503)
9. Urbanic JJ, Lee WR. Update on brachytherapy in localized prostate cancer: the importance of dosimetry. Curr Opin Urol. 2006;16:157-161.
10. Stock RG, Stone NN, Tabert A, et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101-108.
11. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys. 2003;57:645-653. (Pubitemid 37194290)
12. Papagikos MA, Deguzman AF, Rossi PJ, et al. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? Brachytherapy. 2005;4:252-258.
13. Potters L, Huang D, Calugaru E, et al. Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology. 2003;62:1073-1077.
14. Lee WR, Bae K, Lawton CA, et al. A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. Brachytherapy. 2006;5:239-243.
15. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327-333.
16. Sylvester JE, Grimm PD, Blasko JC, et al. 15-year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007;67:57-64.
17. Lawton CA, DeSilvio M, Lee WR, et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys. 2007;67:39-47.
18. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25-33.
19. Feigenberg SJ, Lee WR, Desilvio ML, et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 2005;62(4):956-964.
20. Downs TM, Sadetsky N, Pasta DJ, et al. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer - data from CaPSURE. J Urol. 2003;170:1822-1827.
21. Frank SJ, Pisters LL, Davis J, et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007;177:2151-2156. (Pubitemid 46726403)
22. Ferrer M, Suarez JF, Guedea F, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:421-432.
23. Shah JN, Wuu CS, Katz AE, et al. Improved biochemical control and clinical disease-free survival with intraoperative versus preoperative preplanning for transperineal interstitial permanent prostate brachytherapy. Cancer J. 2006;12:289-297.
24. Zelefsky MJ, yamada y, Marion C, et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:956-963.
25. Wallner K, Merrick G, True L, et al. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003;57:1297-1303.
26. Bice WS, Prestidge BR, Kurtzman SM, et al. Recommendations for permanent prostate brachytherapy with (131)Cs: A consensus report from the Cesium Advisory Group. Brachytherapy. 2008;7:290-296.
27. Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007;67:1106-1112.
28. Older RA, Synder B, Krupski TL, et al. Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy. J Urol. 2001;165:1590-1602. (Pubitemid 32410248)
29. Reed DR, Wallner KE, Merrick GS, et al. A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. Brachytherapy. 2007;6:129-134.
30. Saibishkumar EP, Borg J, yeung I, et al. Loose seeds vs. stranded seeds: a comparison of critical organ dosimetry and acute toxicity in (125)I permanent implant for low-risk prostate cancer. Brachytherapy. 2008;7:200-205.
31. Wallner K, Merrick G, True L, et al. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial. Radiother Oncol. 2005;75:307-310.
32. Kuban DA, Potters L, Lawton CA, et al. Prostate Cancer. In: Halperin EC, Perez CA, Brady LW. Perez and Brady's Principles and Practice of Radiation Oncology. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008.
33. Crook J. Phase II Study of Transperineal Ultrasound-Guided Iodine I 125 or Palladium Pd 103 Brachytherapy in Patients With Locally Recurrent Adenocarcinoma of the Prostate Previously Treated With External-Beam Radiotherapy. 2008. Radiation Therapy Oncology Group, www.rtog.org/0526. Accessed November 1, 2009.
34. Wallner K, Sylvester JE, Merrick G. Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial. 2008. Schiffler Cancer Center, Wheeling, West Virginia. www.Clinicaltrials.gov/NCT00243646. Accessed November 1, 2009.
35. Prestidge B. Phase III Randomized Study of Interstitial Brachytherapy With or Without External Beam Radiotherapy in Patients With Intermediate-Risk Prostate Cancer. 2008. Radiation Therapy Oncology Group, www.rtog.org/0232. Accessed November 1, 2009.
36. Merrick G. Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial. In: Wallner K, editor.; 2008. Schiffler Cancer Center, Wheeling, West Virginia. www.Clinicaltrials.gov/NCT00247312. Accessed November 1, 2009.
37. Nieh PT. Botulinum Toxin Injection With Prostate Brachytherapy. 2008. Emory Univerisity. www.Clinicaltrials.gov/NCT00681148. Accessed November 1, 2009.
38. Mohler J. Phase II Randomized Study of Selenomethionine Supplementation in Patients Undergoing Prostatectomy or Brachytherapy for Stage I or II Prostate Cancer. 2008. Roswell Park Cancer Institute, Buffalo, Ny, USA. www.Clinicaltrials.gov/NCT00736164. Accessed November 1, 2009.
39. yee D. High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation. 2008. Cross Cancer Institute, Edmonton, AB, Canada. www.Clinicaltrials.gov/NCT00126854. Accessed November 1, 2009.
40. Slobada R. Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy. 2008. Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada. www.Clinicaltrials.gov/NCT00127816. Accessed November 1, 2009.
41. Song D. Study of Robotic Template Guidance for Needle Placement in Transperineal Prostate Brachytherapy. In: DiPasquale S, editor.; 2008. Sidney Kimmel Comprehesive Cancer Center, John Hopkins University, Baltimore, MD. www.Clinicaltrials.gov/NCT00381966. Accessed November 1, 2009.
42. Morris WJ. Intensity Modulated Versus Interstitial - Radiation Therapy. 2008. British Columbia Cancer Agency, Vancouver, BC, Canada. www.Clinicaltrials.gov/NCT00407875. Accessed November 1, 2009.
43. Nobes JP, Wells IG, Khaksar SJ, et al. Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience. Prostate Cancer Prostatic Dis. 2009;12:61-66.
44. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839-850.
45. Lawton C, DeSilvio M, Lee WR, et al. Results of a Prospective Multi-Institutional Phase II Trial (RTOG 98-05) of Transrectal Ultrasound Guided Permanent Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prostate. Int J Radiat Oncol Biol Phys. 2004;60:S184-185.
46. Sylvester J, Blasko J, Grimm P, et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle Experience. Int J Radiat Oncol Biol Phys. 2003;57:944-952. (Pubitemid 37324111)
47. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28:555-565.
48. Jani AB, Feinstein JM, Pasciak R, et al. Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer. Urology. 2006;67:1007-1011.
49. Jani AB, Shoushtari A, Feinstein JM. Role of androgen ablation with low-dose-rate brachytherapy in the treatment of prostate cancer. Clin Drug Investig. 2006;26:723-731. (Pubitemid 44901701)
50. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2008;179(5 Suppl):S20-24.
51. Stock RG, Cesaretti JA, Stone NN. Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys. 2006;64:810-816.
52. Merrick GS, Butler WM, Galbreath RW et al. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys. 2002;52:664-673.
53. Critz FA and Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol. 2004;172:2232-2238. (Pubitemid 39507498)